









Markets
/
Stocks
/
nasdaq-atxs
/

Astria Therapeutics Inc

ATXS

12.580USD

0.0000.00%

Close 02/06, 16:00（ET）Quotes delayed by 15 min

709.95MMarket Cap

LossP/E TTM



Astria Therapeutics Inc

12.580

0.0000.00%

Overview Financials Analysis Company

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

Overview

Financials

Analysis

Company

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

TradingKey Stock Score of Astria Therapeutics Inc

Currency: USD Updated: 2026-01-22

Key Insights

Astria Therapeutics Inc's fundamentals are relatively very healthy, and its growth potential is significant.Its valuation is considered fairly valued, ranking 88 out of 395 in the Biotechnology & Medical Research industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Hold, with the highest price target at 21.20.In the medium term, the stock price is expected to remain stable.Despite an average stock market performance over the past month, the company shows strong fundamentals and technicals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

Astria Therapeutics Inc's Score

Industry at a Glance

Industry Ranking

88 / 395

Overall Ranking

192 / 4546

Industry

Biotechnology & Medical Research

Support & Resistance

Relevant data have not been disclosed by the company yet.

Score Analysis

Current score

Previous score

Media Coverage

Last 24 hours

Coverage Level

Very Low

Very High

Neutral

Astria Therapeutics Inc Highlights

StrengthsRisks

Astria Therapeutics, Inc. is a biopharmaceutical company focused on the discovery, development and commercialization of novel therapeutics for allergic and immunological diseases. Its lead product candidate is Navenibart, a potential monoclonal antibody inhibitor of plasma kallikrein in clinical development for the treatment of hereditary angioedema (HAE), a rare, autosomal dominant genetic disorder. Its second product candidate is STAR-0310, a monoclonal antibody OX40 antagonist that is in clinical development for the treatment of atopic dermatitis (AD), an immune disorder associated with loss of skin barrier function and itching. It owns five patent families directed to navenibart. The first patent family is directed to the composition of matter of navenibart and its use in treating various plasma kallikrein associated disorders, including HAE. In the second patent family, it is directed to methods of treating various plasma-kallikrein-associated disorders, including HAE.

High Profit Growth

The company's net income leads the industry, with the latest annual income totaling USD 0.00.

Undervalued

The company’s latest PE is -5.88, at a low 3-year percentile range.

Institutional Selling

The latest institutional holdings are 50.80M shares, decreasing 12.19% quarter-over-quarter.

Held by James Simons

Star Investor James Simons holds 395.26K shares of this stock.

Analyst Rating

Based on 3 analysts

Hold

Current Rating

13.000

Target Price

+3.34%

Upside Space

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Financial Health

Currency: USD Updated: 2026-01-22

The current financial score of Astria Therapeutics Inc is 8.21, ranking 58 out of 395 in the Biotechnology & Medical Research industry. Its financial status is robust, and its operating efficiency is high.

Score

Industry at a Glance

Previous score

8.21

Change



Financials

8.00

Key Metrics

Cash and cash equivalents

Total assets

Total liabilities

Free cash flow

Relevant data have not been disclosed by the company yet.



Quality of Earnings

10.00

Key Metrics

Total revenue

Operating profit

Total assets

SG&A

Relevant data have not been disclosed by the company yet.



Operational Efficiency

10.00

Key Metrics

Cash flow from operating activities

Income after tax

Relevant data have not been disclosed by the company yet.



Growth Potential

5.70

Key Metrics

Cash flow from operating activities

Total revenue

Relevant data have not been disclosed by the company yet.



Shareholder Returns

7.33

Key Metrics

Free cash flow

Relevant data have not been disclosed by the company yet.

Astria Therapeutics Inc's Company Valuation

Currency: USD Updated: 2026-01-22

The current valuation score of Astria Therapeutics Inc is 6.17, ranking 323 out of 395 in the Biotechnology & Medical Research industry. Its current P/E ratio is -5.88, which is -66.05% below the recent high of -2.00 and -17.28% above the recent low of -6.90.

Score

Industry at a Glance

Previous score

6.17

Change

Valuation Dimensions

P/E

P/B

P/S

P/CF

Industry Ranking 88/395

Relevant data have not been disclosed by the company yet.

Earnings Forecast

Currency: USD Updated: 2026-01-22

The current earnings forecast score of Astria Therapeutics Inc is 6.25, ranking 342 out of 395 in the Biotechnology & Medical Research industry. The average price target is 13.00, with a high of 35.00 and a low of 13.00.

Score

Industry at a Glance

Previous score

6.25

Change

Support & Resistance

Relevant data have not been disclosed by the company yet.

Analyst Rating

Based on 3 analysts

Hold

Current Rating

13.000

Target Price

+3.34%

Upside Space

Strong Buy

Buy

Hold

Sell

Strong Sell

Peer Comparison

542

Total

Median

Average

Company name

Ratings

Analysts

Astria Therapeutics Inc

ATXS

CRISPR Therapeutics AG

CRSP

argenx SE

ARGX

IQVIA Holdings Inc

IQV

Intellia Therapeutics Inc

NTLA

Beigene Ltd

ONC

...

109

Financial Forecasting

EPS

Revenue

Net Profit

EBIT

Relevant data have not been disclosed by the company yet.

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Price Momentum

Currency: USD Updated: 2026-01-22

The current price momentum score of Astria Therapeutics Inc is 6.38, ranking 277 out of 395 in the Biotechnology & Medical Research industry. Currently, the stock price is trading between the resistance level at 13.16 and the support level at 12.12, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Previous score

6.24

Change

0.14

Support & Resistance

Relevant data have not been disclosed by the company yet.

Indicators



The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.

This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.

Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.

Indicators

Sell(2)

Neutral(4)

Buy(1)

Indicators

Value

Direction

MACD(12,26,9)

-0.123

Neutral

RSI(14)

46.093

Neutral

STOCH(KDJ)(9,3,3)

27.313

Neutral

ATR(14)

0.256

Low Volatility

CCI(14)

-67.751

Neutral

Williams %R

67.464

Sell

TRIX(12,20)

-0.080

Sell

StochRSI(14)

48.163

Buy

Moving Average

Sell(3)

Neutral(0)

Buy(3)

Indicators

Value

Direction

MA5

12.560

Buy

MA10

12.643

Sell

MA20

12.809

Sell

MA50

12.745

Sell

MA100

11.026

Buy

MA200

8.278

Buy

Institutional Confidence

Currency: USD Updated: 2026-01-22

The latest institutional shareholding proportion is 126.27%, representing a quarter-over-quarter decrease of 2.62%. The largest institutional shareholder is The Vanguard, holding a total of 2.64M shares, representing 4.63% of shares outstanding, with 1.10% decrease in holdings.

Score

Industry at a Glance

Previous score

10.00

Change

Institutional Shareholding

Relevant data have not been disclosed by the company yet.

Shareholder Activity

Name

Shares Held

Chg %

Perceptive Advisors LLC

6.49M

Vestal Point Capital, LP

4.96M

+9.60%

Magnetar Capital Partners LP

3.31M

Glazer Capital, LLC

3.16M

BlackRock Institutional Trust Company, N.A.

2.92M

-8.16%

Fidelity Management & Research Company LLC

2.80M

-23.43%

TCG Crossover Management, LLC

2.76M

The Vanguard Group, Inc.

Star Investors

2.64M

+4.65%

VR Adviser, LLC

2.46M

J.P. Morgan Securities LLC

1.66M

-0.67%

Risk Assessment

Currency: USD Updated: 2026-01-22

The U.S. Dollar Index is currently in a neutral state, which has a neutral effect on the Biotechnology & Medical Research domestic-focused industry. The Dollar Index (DXY) measures the value of the U.S. dollar against a basket of major currencies, including the euro, yen, pound sterling, Canadian dollar, Swedish krona, and Swiss franc. The current risk assessment score of Astria Therapeutics Inc is 4.99, ranking 61 out of 395 in the Biotechnology & Medical Research industry. The company's beta value is 0.21. This indicates that the stock tends to underperform the index during upward trending markets but experiences smaller declines during downward trending markets.